194 related articles for article (PubMed ID: 9311802)
1. Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo.
Ethelberg S; Lovmand J; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Oct; 71(10):7273-80. PubMed ID: 9311802
[TBL] [Abstract][Full Text] [Related]
2. Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants.
Amtoft HW; Sørensen AB; Bareil C; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Jul; 71(7):5080-7. PubMed ID: 9188573
[TBL] [Abstract][Full Text] [Related]
3. Second-site proviral enhancer alterations in lymphomas induced by enhancer mutants of SL3-3 murine leukemia virus: negative effect of nuclear factor 1 binding site.
Ethelberg S; Hallberg B; Lovmand J; Schmidt J; Luz A; Grundström T; Pedersen FS
J Virol; 1997 Feb; 71(2):1196-206. PubMed ID: 8995642
[TBL] [Abstract][Full Text] [Related]
4. Mutation of all Runx (AML1/core) sites in the enhancer of T-lymphomagenic SL3-3 murine leukemia virus unmasks a significant potential for myeloid leukemia induction and favors enhancer evolution toward induction of other disease patterns.
Sørensen KD; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
J Virol; 2004 Dec; 78(23):13216-31. PubMed ID: 15542674
[TBL] [Abstract][Full Text] [Related]
5. Increased induction of osteopetrosis, but unaltered lymphomagenicity, by murine leukemia virus SL3-3 after mutation of a nuclear factor 1 site in the enhancer.
Ethelberg S; Tzschaschel BD; Luz A; Diaz-Cano SJ; Pedersen FS; Schmidt J
J Virol; 1999 Dec; 73(12):10406-15. PubMed ID: 10559359
[TBL] [Abstract][Full Text] [Related]
6. Selection of reversions and suppressors of a mutation in the CBF binding site of a lymphomagenic retrovirus.
Martiney MJ; Rulli K; Beaty R; Levy LS; Lenz J
J Virol; 1999 Sep; 73(9):7599-606. PubMed ID: 10438850
[TBL] [Abstract][Full Text] [Related]
7. An SL3-3 murine leukemia virus enhancer variant more pathogenic than the wild type obtained by assisted molecular evolution in vivo.
Ethelberg S; Sørensen AB; Schmidt J; Luz A; Pedersen FS
J Virol; 1997 Dec; 71(12):9796-9. PubMed ID: 9371648
[TBL] [Abstract][Full Text] [Related]
8. Importance of a c-Myb binding site for lymphomagenesis by the retrovirus SL3-3.
Nieves A; Levy LS; Lenz J
J Virol; 1997 Feb; 71(2):1213-9. PubMed ID: 8995644
[TBL] [Abstract][Full Text] [Related]
9. B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.
Lovmand J; Sorensen AB; Schmidt J; Ostergaard M; Luz A; Pedersen FS
J Virol; 1998 Jul; 72(7):5745-56. PubMed ID: 9621033
[TBL] [Abstract][Full Text] [Related]
10. Suppressor mutations within the core binding factor (CBF/AML1) binding site of a T-cell lymphomagenic retrovirus.
Martiney MJ; Levy LS; Lenz J
J Virol; 1999 Mar; 73(3):2143-52. PubMed ID: 9971797
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional activity of core binding factor-alpha (AML1) and beta subunits on murine leukemia virus enhancer cores.
Zaiman AL; Lewis AF; Crute BE; Speck NA; Lenz J
J Virol; 1995 May; 69(5):2898-906. PubMed ID: 7707514
[TBL] [Abstract][Full Text] [Related]
12. Analysis of wild-type and mutant SL3-3 murine leukemia virus insertions in the c-myc promoter during lymphomagenesis reveals target site hot spots, virus-dependent patterns, and frequent error-prone gap repair.
Nielsen AA; Sørensen AB; Schmidt J; Pedersen FS
J Virol; 2005 Jan; 79(1):67-78. PubMed ID: 15596802
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.
Zaiman AL; Lenz J
J Virol; 1996 Aug; 70(8):5618-29. PubMed ID: 8764076
[TBL] [Abstract][Full Text] [Related]
14. CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
Zaiman AL; Nieves A; Lenz J
J Virol; 1998 Apr; 72(4):3129-37. PubMed ID: 9525638
[TBL] [Abstract][Full Text] [Related]
15. Enhancer mutations of Akv murine leukemia virus inhibit the induction of mature B-cell lymphomas and shift disease specificity towards the more differentiated plasma cell stage.
Sørensen KD; Kunder S; Quintanilla-Martinez L; Sørensen J; Schmidt J; Pedersen FS
Virology; 2007 May; 362(1):179-91. PubMed ID: 17258785
[TBL] [Abstract][Full Text] [Related]
16. The feline leukemia virus long terminal repeat contains a potent genetic determinant of T-cell lymphomagenicity.
Pantginis J; Beaty RM; Levy LS; Lenz J
J Virol; 1997 Dec; 71(12):9786-91. PubMed ID: 9371646
[TBL] [Abstract][Full Text] [Related]
17. SL3-3 enhancer factor 1 transcriptional activators are required for tumor formation by SL3-3 murine leukemia virus.
Hallberg B; Schmidt J; Luz A; Pedersen FS; Grundström T
J Virol; 1991 Aug; 65(8):4177-81. PubMed ID: 1649324
[TBL] [Abstract][Full Text] [Related]
18. Long terminal repeat enhancer core sequences in proviruses adjacent to c-myc in T-cell lymphomas induced by a murine retrovirus.
Morrison HL; Soni B; Lenz J
J Virol; 1995 Jan; 69(1):446-55. PubMed ID: 7983741
[TBL] [Abstract][Full Text] [Related]
19. Distinct roles of enhancer nuclear factor 1 (NF1) sites in plasmacytoma and osteopetrosis induction by Akv1-99 murine leukemia virus.
Sørensen KD; Sørensen AB; Quintanilla-Martinez L; Kunder S; Schmidt J; Pedersen FS
Virology; 2005 Apr; 334(2):234-44. PubMed ID: 15780873
[TBL] [Abstract][Full Text] [Related]
20. Contributions to transcriptional activity and to viral leukemogenicity made by sequences within and downstream of the MCF13 murine leukemia virus enhancer.
Tupper JC; Chen H; Hays EF; Bristol GC; Yoshimura FK
J Virol; 1992 Dec; 66(12):7080-8. PubMed ID: 1331510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
